151 related articles for article (PubMed ID: 35022197)
1. Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy.
Onitilo AA; Piwuna TO; Islam N; Furuya-Kanamori L; Kumar S; Doi SAR
Clin Med Res; 2022 Mar; 20(1):16-22. PubMed ID: 35022197
[No Abstract] [Full Text] [Related]
2. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Xiao L; Salem JE; Clauss S; Hanley A; Bapat A; Hulsmans M; Iwamoto Y; Wojtkiewicz G; Cetinbas M; Schloss MJ; Tedeschi J; Lebrun-Vignes B; Lundby A; Sadreyev RI; Moslehi J; Nahrendorf M; Ellinor PT; Milan DJ
Circulation; 2020 Dec; 142(25):2443-2455. PubMed ID: 33092403
[TBL] [Abstract][Full Text] [Related]
4. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
[TBL] [Abstract][Full Text] [Related]
5. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Lentz R; Feinglass J; Ma S; Akhter N
Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation.
Yang X; An N; Zhong C; Guan M; Jiang Y; Li X; Zhang H; Wang L; Ruan Y; Gao Y; Liu N; Shang H; Xing Y
Redox Biol; 2020 Feb; 30():101432. PubMed ID: 31986467
[TBL] [Abstract][Full Text] [Related]
10. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib.
Singh A; El Hangouche N; McGee K; Gong FF; Lentz R; Feinglass J; Akhter N
Echocardiography; 2021 Jan; 38(1):81-88. PubMed ID: 33594858
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib.
Avalon JC; Fuqua J; Miller T; Deskins S; Wakefield C; King A; Inderbitzin-Brooks S; Bianco C; Veltri L; Fang W; Craig M; Kanate A; Ross K; Malla M; Patel B
Cardiooncology; 2021 Nov; 7(1):38. PubMed ID: 34798905
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
Ciuculete DC; Popescu RA; Dan GA
Rom J Intern Med; 2021 Sep; 59(3):270-277. PubMed ID: 33913303
[TBL] [Abstract][Full Text] [Related]
14. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib-related atrial fibrillation: A single center Australian experience.
Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
[TBL] [Abstract][Full Text] [Related]
16. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.
Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Lip GY
Eur J Heart Fail; 2013 Apr; 15(4):415-24. PubMed ID: 23302606
[TBL] [Abstract][Full Text] [Related]
17. Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study.
Mattiello V; Barone A; Giannarelli D; Noto A; Cecchi N; Rampi N; Cassin R; Reda G
Hematol Oncol; 2023 Aug; 41(3):363-370. PubMed ID: 36762406
[TBL] [Abstract][Full Text] [Related]
18. Right atrial structure and function in patients with hypertension and with chronic heart failure.
Proplesch M; Merz AA; Claggett BL; Lewis EF; Dwyer KH; Crousillat DR; Lau ES; Silverman MB; Peck J; Rivero J; Cheng S; Platz E
Echocardiography; 2018 Jul; 35(7):905-914. PubMed ID: 29600555
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib-Associated Atrial Fibrillation.
Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
